The Technical Analyst
Solid Biosciences Inc [SLDB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Solid Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
2.27% $9.25
America/New_York / 23 apr 2024 @ 13:21
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 349.06 mill |
| EPS: | -4.83 |
| P/E: | -1.910 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 37.76 mill |
| Avg Daily Volume: | 0.262 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.910 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.32x |
| Company: PE -1.910 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.40 (-74.02%) $-6.84 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 8.00 - 10.60 ( +/- 13.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Smith Ian F | Buy | 3 256 | Common Stock |
| 2024-04-03 | Smith Ian F | Sell | 3 256 | Restricted Stock Units |
| 2024-02-13 | Hanrahan Jessie | Buy | 65 000 | Employee Stock Option (Right to Buy) |
| 2024-02-13 | Hanrahan Jessie | Buy | 32 500 | Restricted Stock Units |
| 2024-02-13 | Cumbo Alexander | Buy | 240 250 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 95.48 |
| Last 96 transactions |
| Buy: 8 088 873 | Sell: 207 617 |
Forecast:
15:00 - $9.30
Live Trading Signals (every 1 min)
Forecast
1: 13:30 - $9.27
Forecast 2: 14:20 - $9.30
Forecast 3: 15:00 - $9.30
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.25 (2.27% ) |
| Volume | 0.181 mill |
| Avg. Vol. | 0.262 mill |
| % of Avg. Vol | 68.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SLDB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $7.31 | N/A | Active |
|---|
SLDB
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-03 16:05:00 - Press Release
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Charlestown, mass., april 03, 2024 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. these grants were made pursuant to the company's 2024 inducement stock incentive plan and were made as an inducement material to each employee's acceptance of employment with the company in accordance with nasdaq listing rule 5635(c)(4).
2024-04-01 07:45:00 - Press Release
Solid Biosciences Receives Rare Pediatric Disease Designation From The Fda For Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003
– sgt-003 granted rare pediatric disease, orphan drug and fast track designations in u.s. – – site initiations scheduled for april; patient dosing expected to begin in q2 2024 – charlestown, mass., april 01, 2024 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the u.s. food and drug administration (fda) has granted rare pediatric disease designation for sgt-003, the company's next-generation duchenne muscular dystrophy (duchenne) gene therapy candidate.
2024-03-13 07:44:00 - Press Release
Solid Biosciences Provides Fourth Quarter And Full-year 2023 Business Update And Financial Results
— company ends 2023 with approximately $123.6 million in cash and investments. combined with gross proceeds from $108.9 million private placement in january, solid has anticipated cash runway into 2026 —
2024-01-16 08:00:00 - Press Release
Solid Biosciences Granted Fda Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003
– patient dosing expected to begin mid-to-late q1 2024 – charlestown, mass., jan. 16, 2024 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (odd) from the u.s. food and drug administration (fda) for sgt-003, the company's next-generation duchenne muscular dystrophy (duchenne) gene therapy candidate.
2024-01-08 07:09:00 - Press Release
Solid Biosciences Announces $109 Million Private Placement
Charlestown, mass., jan. 08, 2024 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about january 11, 2024, subject to the satisfaction of customary closing conditions. the private placement is being conducted in accordance with applicable nasdaq rules and was priced to satisfy the “minimum price” requirement (as defined in the nasdaq rules).
Latest News
2024-04-10 19:32:53 - Seeking Alpha
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.
2024-04-05 04:54:48 - Finbold
How this insider trader nailed every single stock trade
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
2024-04-02 11:36:05 - Zacks Investment Research
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
2024-02-18 11:20:54 - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
2024-01-24 11:29:00 - Market Watch
Joe Lewis, billionaire owner of Tottenham Hotspur football club, pleads guilty to insider trading
British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.
2024-01-20 10:49:26 - 24/7 Wall Street
More Big Warren Buffett Purchases Highlight Recent Insider Buying
The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.
2024-01-17 12:31:07 - Zacks Investment Research
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
2024-01-16 23:01:41 - Seeking Alpha
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.
2024-01-15 12:02:25 - Zacks Investment Research
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
2023-12-08 06:46:07 - Zacks Investment Research
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.